Adlai Nortye Ltd.
ANLNext catalyst
No upcoming catalyst in our data
No upcoming FDA decision, filing or trial readout is on file for ANL. That does not mean none is planned.
Get an email about ANL's next catalysts
Track Adlai Nortye (ANL) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
0 upcoming, 0 past
No catalysts found.
Market Overview
Stock performance and key metrics
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Buparlisib & Paclitaxel | Phase 3 | Head and Neck Cancer | - | - |
Frequently asked questions
What is in Adlai Nortye Ltd.'s drug pipeline?→
CatalystAlert tracks 1 drug candidate in Adlai Nortye Ltd.'s (ANL) pipeline across Phase 3. Its lead program is Buparlisib & Paclitaxel (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Adlai Nortye Ltd.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Adlai Nortye Ltd. (ANL) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track ANL biotech catalysts?→
Add ANL to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Adlai Nortye Ltd.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.